免責聲明
本網站僅提供窩客幫資訊參考平台, 並不涉入其中任何諮詢、交易。本網站對各該窩客幫相關資訊亦不作任何實質或形式上之審查。本網站中所載一切窩客幫的資訊、文字、照片、圖形 、產權、廣告內容、或其他資料(以下簡稱『內容』)。無論其為公開張貼或私下傳送,若有不實或違法情事,均為『內容』提供者之責任,窩客幫概不負責也不承擔任何法律責任。
豐華生物科技股份有限公司
文章管理
2025.1.10 Totipro® Wins National Innovation Awards — Redefining the Future of Postbiotics
Glac Biotech’s pioneering postbiotic ingredient, Totipro®, continues to shine on both domestic and international stages. First honored with the National Innovation Award in 2019, Totipro® reached another milestone in 2024, earning the National Innovation Excellence Award — a testament to its enduring impact and innovation in the health and nutrition industry.

The Breakthrough: HeaLAC® Heat-Lock Technology
At the heart of Totipro® lies Glac’s patented HeaLAC® heat-lock process, a breakthrough that preserves the bioactive metabolites of probiotics after fermentation. This ensures Totipro® retains nutrient-rich postbiotic compounds while delivering superior stability.
Unlike traditional probiotics, Totipro® is heat-resistant, stable, and versatile, making it suitable for capsules, sachets, protein powders, gummies, and beverages. For food and supplement manufacturers, this flexibility opens the door to next-generation formulations that meet evolving consumer needs.

Tailored Solutions for Gut Health
Recognizing that different sections of the digestive tract face unique challenges, Glac developed two targeted Totipro® solutions:
  • Upper GI tract: Supports oral-to-stomach microbiome balance.
  • Lower GI tract: Strengthens intestinal mucosa, boosts beneficial bacteria, and optimizes gut ecology.
This dual approach positions Totipro® as a comprehensive solution for digestive wellness.

Global Recognition and Patents
Totipro® has already secured patents in Taiwan, the U.S., Japan, and the EU, validating its scientific and commercial value.
Its proven benefits — from oral and gastric health to microbiome support and bowel regularity — have also earned international acclaim. In 2023 and 2024, Totipro® was awarded the NutraIngredients Microbiome Modulation Award two years in a row, cementing its status as a global leader in postbiotics.

Looking Ahead: Clinical Research and Market Positioning
Glac Biotech isn’t slowing down. In 2025, the company will partner with leading teaching hospitals to expand clinical trials on Totipro®, strengthening its scientific foundation and clarifying its position in the global health market.
For Glac, the journey of Totipro® is more than just innovation — it’s about transforming scientific breakthroughs into real-world health solutions.

 

 

Media Coverage (Extended Reading)

 

相關文章
豐華生物科技股份有限公司
電話 : +886-6-589-1876 地址 : 1 F., No. 139, Sanmin St., Xinshi Dist., Tainan City 744007, Taiwan (R.O.C.) 信箱 : glac@glac.com.tw

  • 服務項目

  • 特別關鍵字